Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Free to healthcare providers. No ads, no sponsorships, no bias.

Intended for USA healthcare providers only.

Browse Clinical Trial Updates

All
ASCO Updates
Breast Cancer
GI Cancers
GU Cancers
GYN Oncology
Hematological Malignancies
Lung Cancer
Skin Cancer
Dr. Andrew Kuykendall describes the safety and tolerability of avapritinib in AdvSM(Video 3/3)

Dr. Andrew Kuykendall describes the safety and tolerability of avapritinib in AdvSM(Video 3/3)

Avapritinib in AdvSM - Safety

Andrew Kuykendall, MD
Hematological Malignancies
Dr. Katy Beckermann describes the safety of erdafitinib and practical strategies for managing patients with FGFR-mutated mUC (Video 3/3)

Dr. Katy Beckermann describes the safety of erdafitinib and practical strategies for managing patients with FGFR-mutated mUC (Video 3/3)

THOR Safety

Katy Beckermann, MD
GU Cancers
Dr. Sara Tolaney discusses the potential impact of 1L sacituzumab govitecan on clinical practice in PDL1+ mTNBC (Video 3/3)

Dr. Sara Tolaney discusses the potential impact of 1L sacituzumab govitecan on clinical practice in PDL1+ mTNBC (Video 3/3)

ASCENT04- Impact on clinical practice

Sara Tolaney, MD
ASCO Updates
Breast Cancer
+1 more
Dr. Hossein Borghaei shows the 6-year results of nivo/ipi + chemo in mNSCLC in patients with squamous histology and high-risk mutations. (Video 2/3)

Dr. Hossein Borghaei shows the 6-year results of nivo/ipi + chemo in mNSCLC in patients with squamous histology and high-risk mutations. (Video 2/3)

CM-9LA Biomarker

Hossein Borghaei, MD
Lung Cancer
Dr. Gregory Vidal discusses safety, tolerability, and NCCN categorization of margetuximab-cmkb in HER2+ mBC (Video 3/3)

Dr. Gregory Vidal discusses safety, tolerability, and NCCN categorization of margetuximab-cmkb in HER2+ mBC (Video 3/3)

SOPHIA- Safety

Gregory Vidal
ASCO Updates
Breast Cancer
+1 more
Dr. Janjigian discusses the addition of durvalumab to FLOT chemotherapy in gastroesophageal cancer (Video 3/3)

Dr. Janjigian discusses the addition of durvalumab to FLOT chemotherapy in gastroesophageal cancer (Video 3/3)

Durvalumab added to FLOT Chemotherapy

Yelena Janjigian, MD
GI Cancers

Why subscribe?

  • Get one-minute, non-promotional, educational videos from distinguished thought leaders
  • Tailored to topics you select
    • Breast Cancer
    • Lung Cancer
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecologic Cancers
    • Hemotologic Malignancies
    • Conference updates and more
  • No spam. No ads. No apps to download.
  • Always free and you can opt-out anytime if you feel this isn’t for you.

Fill out the form above to subscribe!

Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Intended for USA healthcare providers only.

If your institution is not listed, please select "Other"

By clicking Subscribe, I agree that I have read and understand IDEOlogy Health’s Privacy Policy and Terms and Conditions and further agree to receive information from IDEOlogy Health and its companies

ideology-health
Privacy Policy
Terms of Service

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.